BLA 761055 · Regeneron Pharmaceuticals
Dupixent
Dupilumab · Injection · Interleukin-4 Receptor alpha Antagonist
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Mar 28, 2017
Approved uses
20
Original approval plus efficacy supplements
Registered trials
220
59 Phase 3, 56 recruiting
FAERS reports
518,489
57,042 serious, 2,351 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 22, 2026.
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous...
Mechanism: Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor. Inflammation driven by IL-4 and IL-13 is an important component in the pathogenesis of asthma, AD, CRSwNP, EoE, PN, COPD, CSU, BP, and AFRS. Multiple cell types that express IL-4Rα (e.g., mast cells, basophils, eosinophils, macrophages, lymphocytes, epithelial...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 22, 2026 Supplement 74 · Efficacy LetterLabel
- Feb 23, 2026 Supplement 75 · Efficacy · priority review LabelLetter
- Jun 18, 2025 Supplement 70 · Efficacy · priority review OrphanLabelLetter
- Apr 17, 2025 Supplement 51 · Efficacy LabelLetter
- Sep 27, 2024 Supplement 64 · Efficacy · priority review Breakthrough therapyLabelLetter
- Sep 12, 2024 Supplement 66 · Efficacy · priority review LabelLetter
- Jan 25, 2024 Supplement 57 · Efficacy · priority review OrphanLabelLetter
- Jan 12, 2024 Supplement 55 · Efficacy OrphanLabelLetter
- Sep 28, 2022 Supplement 44 · Efficacy · priority review LabelLetter
- Jun 7, 2022 Supplement 42 · Efficacy · priority review Breakthrough therapyLetterLabel
- May 20, 2022 Supplement 40 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Oct 20, 2021 Supplement 31 · Efficacy LetterLabel
- Jun 14, 2021 Supplement 16 · Efficacy LetterLabel
- Jun 18, 2020 Supplement 17 · Efficacy LetterLabelReview
- May 26, 2020 Supplement 20 · Efficacy · priority review LabelLetter
- Jun 26, 2019 Supplement 14 · Efficacy · priority review LetterLabelReview
- Mar 11, 2019 Supplement 12 · Efficacy · priority review Breakthrough therapyLabelLetterReview
- Oct 19, 2018 Supplement 7 · Efficacy LabelLetterReview
- Apr 10, 2018 Supplement 3 · Efficacy LabelLetter
- Mar 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLetterLabelReview
1 products under this application
- DUPIXENT · DUPILUMAB 150MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dupilumab" as an intervention, any sponsor and status, largest first.
- Open-label Study of Dupilumab in Patients With Atopic DermatitisPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT01949311 · 2,733 participants · Start Oct 10, 2013 · Primary completion Jun 27, 2022
Drug: Dupilumab · For: Atopic Dermatitis
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 432 sites in all
- Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02134028 · 2,282 participants · Start Aug 5, 2014 · Primary completion Oct 11, 2019
Drug: Dupilumab · For: Asthma
Sites: Birmingham, Alabama; Gilbert, Arizona; Scottsdale, Arizona · 365 sites in all
- Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02414854 · 1,902 participants · Start Apr 27, 2015 · Primary completion Jul 29, 2017
Drug: Dupilumab; Placebo and 3 more · For: Asthma
Sites: Birmingham, Alabama; Flagstaff, Arizona; Gilbert, Arizona · 389 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07783425 · 1,375 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 8, 2028
Drug: Tilrekimig; Dupilumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 50 sites in all
- Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe AsthmaPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05097287 · 1,339 participants · Start Dec 16, 2021 · Primary completion Mar 16, 2027
Drug: Dupilumab; Placebo · For: Asthma
Sites: Cullman, Alabama; Sheffield, Alabama; Chandler, Arizona · 249 sites in all
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT03930732 · 939 participants · Start Apr 15, 2019 · Primary completion Feb 8, 2023
Drug: Dupilumab SAR231893; Inhaled Corticosteroid and 3 more · For: Chronic Obstructive Pulmonary Disease
Sites: Andalusia, Alabama; Birmingham, Alabama; Dothan, Alabama · 275 sites in all
- Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04456673 · 935 participants · Start Jul 6, 2020 · Primary completion Feb 28, 2024
Drug: Dupilumab SAR231893; Inhaled Corticosteroid and 3 more · For: Chronic Obstructive Pulmonary Disease
Sites: Cullman, Alabama; Jasper, Alabama; Scottsboro, Alabama · 334 sites in all
- A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05601882 · 920 participants · Start Nov 28, 2022 · Primary completion Mar 19, 2024
Drug: Dupilumab; Upadacitinib · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Fayetteville, Arkansas; North Little Rock, Arkansas · 257 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pruritus65,143
- dermatitis atopic48,270
- product use in unapproved indication44,555
- rash41,246
- injection site pain40,378
- drug ineffective32,504
- dry skin28,839
- eczema28,786
- product dose omission issue25,576
- condition aggravated21,742
- arthralgia20,813
- inappropriate schedule of product administration19,713
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2016 | 7 |
| 2017 | 1,107 |
| 2018 | 7,626 |
| 2019 | 14,912 |
| 2020 | 20,259 |
| 2021 | 40,308 |
| 2022 | 58,512 |
| 2023 | 66,771 |
| 2024 | 88,410 |
| 2025 | 114,890 |
| 2026 | 105,685 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Bhatt SP, Rabe KF, Hanania NA, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.
Drucker AM, Lam M, Prieto-Merino D, et al. · JAMA Dermatol 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, Han JK, Desrosiers M, et al. · Lancet 2019 · Clinical Trial, Phase III, Multicenter Study
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Comparative Study
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.